Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT01131039 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT01131039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01131039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2011
Completion date
September 30, 2011
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, ovarian cancer, primary peritoneal